GlassScriptPhysician profile
Debra M Gibson
NPI 1588636260
$2,003.27
in general payments reported to CMS, 2019-2025
10 companies · $549 in 2025
The $549 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89.79 · 2021: $377 · 2022: $124 · 2023: $492 · 2024: $371 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,412.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,412.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $699.96 | 2022-2025 | Augment Injectable, Actishield, Ortholoc 2 Lapifuse |
| Organogenesis INC. | $673.86 | 2021-2025 | Puraply Wound Matrix, Puraply Franchise, Puraply Am |
| Musculoskeletal Transplant Foundation INC. | $220.44 | 2021 | |
| Kerecis Limited | $117.42 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Paratek Pharmaceuticals, INC. | $107.95 | 2023 | Nuzyra |
| Horizon Therapeutics Plc | $89.79 | 2019 | |
| Nevro Corp. | $36.96 | 2024 | Senza |
| Paragon 28, INC. | $31.22 | 2024 | Mini Monster |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.33 | 2024 | Jublia |
| Triad Life Sciences INC. | $12.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.